Navigation Links
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
Date:1/10/2014

ately $212 million in cash, cash equivalents, and available for sale securities.  Rigel expects to end 2014 with cash, cash equivalents, and available for sale securities in excess of $132 million, which is sufficient to fund its operations through the second quarter of 2016.

Webcast details
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP and a Phase 2 clinical trial for IgA nephropathy in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an AMPK activator entering Phase 1 in early 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.

This press release contains "forward-looking" statements, including, without limitation, statements related to development plans, the timing of planned clinical trials and results, milestone payments, and Rigel's ability to fund and maintain its current development plans into 2016.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "w
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Oppenheimer Healthcare Conference
2. Rigel Announces Third Quarter 2013 Financial Results
3. Rigel Provides Pipeline Update
4. Rigel to Present at Stifel Healthcare Conference
5. Rigel To Focus On ITP, DLE And Dry Eye
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. Rigel Announces Second Quarter 2013 Financial Results
8. Rigel Will Resume Responsibility for Fostamatinib Program
9. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
10. Rigel Announces First Quarter 2013 Financial Results
11. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ... the past decade has seen the atopic ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger ... and painless for patients to self-inject prescription drugs in ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and ... market is expected to grow to $220B by 2018, ... a new type of injector that does not exist ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ... and Pittsburgh markets. Progressive was founded ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... N.J., Dec. 7, 2011 Updated results of ... plus exemestane, a hormonal therapy, show everolimus provided ... without their disease progressing (progression-free survival)(1). ... months of follow-up, were presented at the 2011 ...
... Dec. 7, 2011 Jia-Hwa Fang, Ph.D., has ... Manufacturing.  In this new role, he will lead ... Laboratory Practice (GLP), and pilot formulations for early ... Manufacturing Practices (GMP).  He will be responsible for ...
Cached Medicine Technology:New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 2New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 3New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 4New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 5New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 6New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 7New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 8New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 9New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 10Jia-Hwa Fang Joins SRI Biosciences as Director of Clinical Manufacturing 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and P4 have clear and distinct effects on inflammatory ... infection. Recently, Ohtani et al., have shown a protective ... Other studies have demonstrated that E2 and P4 have ... been reported in human, mouse and rat stomach. However, ...
... Allergy Testing in Improving Asthma ... ... Health announced today,that it has entered a co-promotion agreement with Phadia, ... in the diagnosis,and treatment of asthma and other respiratory diseases. Under ...
... Oct. 31 In the final 72-hours of,this ... volunteers,across the country are joining 4,000 SEIU members, ... the job to bring home victory for,Barack Obama, ... working,families need., SEIU,s major GOTV operations are ...
... an exaggerated intestinal immune response to otherwise innocuous ... plays a key role in the pathophysiology of ... yet emerged. Vitamin E is a major lipophilic ... which protects membrane lipids from peroxidation by scavenging ...
... to sign up online at http://www.diabetesatlanta.org , ATLANTA, ... than 600,000 Georgians, could be present in more than,300,000 more, ... disease?, No. The answer is diabetes., And, new ... the U.S. has,nearly doubled in the past 10 years - ...
... Array of Colors and,Custom Products Giving Confident Wearers ... PISCATAWAY, N.J., Oct. 31 Siemens Hearing,Instruments, Inc., ... States, continues their commitment to personalizing solutions for,those ... hearing instruments,were announced at this year,s International Congress ...
Cached Medicine News:Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 3Health News:Nation's #1 Respiratory Hospital Enters Agreement to Co-Promote IgE Blood Testing 2Health News:In Final 72-Hour Push, SEIU Members Get Out The Vote for Barack Obama and Other Working Family Candidates Across the Country 2Health News:Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis? 2Health News:As Diabetes Reaches Epidemic Levels in Georgia and U.S., Thousands Drawn to Diabetes University in Atlanta Nov. 8 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 3Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 4
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: